Ulrich Naher
CIK 1686743 · View on SEC EDGAR ↗
First SEC filing: March 10, 2022 · Latest: March 10, 2022
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 4, 2019 | DBD | P | 30,000 | $7.90 | $237,000 | 195,202 Direct | +18.16% | Acquired | 753.0% (price as of 2026-08-20) |
| March 13, 2019 | DBD | P | 10,000 | $10.21 | $102,100 | 165,202 Direct | +6.44% | Acquired | 560.0% (price as of 2026-08-20) |
| March 12, 2019 | DBD | P | 10,000 | $10.06 | $100,600 | 155,202 Direct | +6.89% | Acquired | 569.9% (price as of 2026-08-20) |
| Feb. 20, 2019 | DBD | P | 13,000 | $8.57 | $111,410 | 145,202 Direct | +9.83% | Acquired | 686.3% (price as of 2026-08-20) |
| Feb. 19, 2019 | DBD | P | 13,000 | $8.43 | $109,590 | 132,202 Direct | +10.91% | Acquired | 699.4% (price as of 2026-08-20) |
| July 24, 2017 | DBD | P | 2,000 | $21.90 | $43,800 | 7,759 Direct | +34.73% | Acquired | 207.7% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 30, 2020 | DBD | Non-Qualified Stock Option [F5] | Common Shares (12,614) | $11.96 | Jan. 30, 2030 | 12,614 | Acquired |
| Jan. 29, 2019 | DBD | Non-Qualified Stock Option [F4] | Common Shares (47,407) | $4.08 | Jan. 29, 2029 | 47,407 | Acquired |
| Feb. 1, 2018 | DBD | Non-Qualified Stock Option [F1,F2] | Common Shares (30,278) | $18.75 | Feb. 1, 2028 | 30,278 | Acquired |
| Feb. 1, 2018 | DBD | Common Shares [F4] | Common Shares (44,427) | $18.70 | Feb. 1, 2028 | 44,427 | Acquired |
| Feb. 8, 2017 | DBD | Non-Qualified Stock Options [F3] | Common Shares (49,650) | $26.60 | Feb. 7, 2027 | 49,650 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
DBD
Chief Commercial Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | — | — | — | — | — | — | $1,723,517 | $3,874,663 |
| 2021 | — | — | — | — | $713,364 | $52,334 | $98,852 | $2,593,428 |
| 2020 | — | — | — | — | $451,430 | $79,450 | $104,149 | $1,606,272 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.